



In the claims

The following amendments are made with respect to the claims in the International application PCT/GB2004/002606.

This listing of claims will replace all prior versions and listings of claims in this application.

1 (Original). A compound of formula (I) or formula (II)



wherein

D is $-(CH_2)_n-$, $-C(=X)-$, $-O-$, $-S(O)_m-$, $-C(=X)N(R^c)-$, $-C(R^b)_2-$, $-C(R^b)=C(R^b)-$, $-CH(R^b)CH(R^b)-$;

E is optionally present and is $-(CH_2)_n-$, $-N(R^d)-$, $-(CH_2)_nN(R^d)-$ or $-N(R^d)(CH_2)_n-$;

F is $-C(=X)-$ or $-N(R^d)-$;

G is $-(CH_2)_n-$, $-N(R^d)-$, $-(CH_2)_nN(R^d)-$ or $-N(R^d)(CH_2)_n-$;

J is optionally present and is $-O-$, $-N(R^c)C(=X)-$, $-C(=X)N(R^c)-$, $-S(O)_m-$, $-N(R^c)S(O)_m-$, $-S(O)_mN(R^c)-$ or $-N(R^c)-$;

K is optionally present and is alkylene optionally substituted with R^b; or K is cycloalkylene, cycloalkenylene, arylene, heterocycloalkylene, heterocycloalkenylene or heteroarylene, any of which is optionally substituted with R^a;

L is hydrogen, halogen, $-N(R^f)_2$, cycloalkyl, cycloalkenyl, aryl, heterocycloalkyl, heterocycloalkenyl or heteroaryl, any of which is optionally substituted with R^a, $-C(=X)OR^d$, $-OH$, $-OR^c$, $-C(=X)N(R^b)(R^c)$, $-S(O)_mN(R^b)(R^c)$ or $-CN$;

each R^a is the same or different and is hydrogen, halogen, alkyl, aryl, hydroxy, alkoxy, $-alkoxy-(CH_2)_nC(O)_2R^b$, $-O-aryl$, $-C(=X)R^c$, $-NO_2$, $-CN$, $-N(R^c)C(=X)R^c$, $-C(=X)N(R^c)_2$, $-S(O)_2N(R^c)_2$ or $-N(R^c)_2$;

each R^b is the same or different and is hydrogen or alkyl;
each R^c is the same or different and is alkyl, cycloalkyl, -alkyl-aryl, -alkyl-cycloalkyl or aryl optionally substituted with R^a ;
each R^d is the same or different and is hydrogen, alkyl or aryl optionally with R^a ;
each R^e is the same or different and is hydrogen, alkyl; or R^e is aryl or heteroaryl, either of which is optionally substituted with R^a ;
each R^f is the same or different and is hydrogen or alkyl; or R^f -N- R^f taken together form heterocycloalkyl, heterocycloalkenyl or heteroaryl;
each X is the same or different and is oxygen or sulphur;
Y and Z are the same or different and are each hydrogen, halogen, alkyl, hydroxy, alkoxy, -CN, -N(R^d)C(=X) R^c , -C(=X)N(R^c)(R^d), -S(O)_m- R^c , -N(R^c)(R^d)S(O)₂, -S(O)₂N(R^c)(R^d), -N(R^c)₂, -Si(R^c)₃, -alkyl-Si(R^c)₃, aryl optionally substituted with R^a or -O-aryl optionally substituted with R^a ;
Rings 1 and 2 are the same or different and are each arylene or heteroarylene, either of which is optionally substituted with R^a ;
each m is the same or different and is 0, 1 or 2; and
each n is the same or different and is 0, 1, 2, or 3;
with the provisos that at least one of Y and Z comprises a silicon atom and that the compound does not comprise a N-N single bond;
or a pharmaceutically acceptable salt thereof.

2 (Currently amended). [[A]] The compound according to claim 1, wherein Y is -Si(R^c)₃, -alkyl-Si(R^c)₃ or hydrogen.

3 (Currently amended). [[A]] The compound according to claim 2, wherein each R^c is the same or different and is alkyl.

4 (Currently amended). [[A]] The compound according to ~~any preceding~~ claim 1, wherein Z is hydrogen, -Si(R^c)₃, -alkyl-Si(R^c)₃, -O-aryl, halogen or alkoxy.

5 (Currently amended). [[A]] The compound to claim 4, wherein each R^c is the same or different and is alkyl or phenyl.

6 (Currently amended). [[A]] The compound according to ~~any preceding~~ claim 1, wherein R^a is alkyl, halogen or alkoxy.

7 (Currently amended). [[A]] The compound according to ~~any preceding~~ claim 1, wherein D is -O-, -S- or -CH₂-.

8 (Currently amended). [[A]] The compound according to ~~any preceding~~ claim 1, wherein E is absent.

9 (Currently amended). [[A]] The compound according to ~~any preceding~~ claim 1, wherein F is -C(O)-.

10 (Currently amended). [[A]] The compound according to ~~any preceding~~ claim 1, wherein G is -N(R^d)-.

11 (Currently amended). [[A]] The compound according to claim 10, wherein R^d is hydrogen.

12 (Currently amended). [[A]] The compound according to ~~any preceding~~ claim 1, wherein J and K are absent, and L is hydrogen or -N(R^f)₂.

13 (Currently amended). [[A]] The compound according to ~~any of~~ claim[[s]] 1 [[to 11]], wherein J is -NH-, K is alkylene and L is heterocycloalkyl.

14 (Currently amended). [[A]] The compound according to ~~any preceding~~ claim 1, wherein Ring 1 is heteroaryl.

15 (Currently amended). [[A]] The compound according to claim 14, wherein Ring 1 is furan.

16 (Currently amended). [[A]] The compound according to ~~any of~~ claim[[s]] 1 [[to 13]], wherein Ring 1 is phenyl.

17 (Currently amended). [[A]] The compound according to ~~any preceding~~ claim 1, wherein Ring 2 is phenylene, pyrimidylene or pyridinylene, any of which is optionally substituted.

18 (Currently amended). [[A]] The compound according to claim 17, wherein Ring 2 is substituted 1, 2 or 3 times, the substituents being the same or different in each occurrence and selected from alkoxy and halogen.

19 (Currently amended). [[A]] The compound according to claim 1, selected from:

5-[2-methyl-5-(trimethylsilyl)phenoxy]-*N*-(2,6-dimethoxyphenyl)furan-2-carboxamide;

5-[2-methyl-5-(trimethylsilyl)phenoxy]-*N*-(2,4,6-trimethoxyphenyl)furan-2-carboxamide;

5-[2-methyl-5-(trimethylsilyl)phenoxy]-*N*-(2,4,6-trimethoxy-1,3-pyrimidin-5-yl)furan-2-carboxamide;

5-[2-methyl-5-(trimethylsilyl)phenoxy]-*N*-(2-methylamino-4,6-dimethoxy-1,3-pyrimidin-5-yl)furan-2-carboxamide;

5-[2-methyl-5-(trimethylsilyl)phenoxy]-*N*-{2-[3-(4-methylpiperazin-1-yl)propylamino]-4,6-dimethoxy-1,3-pyrimidin-5-yl}furan-2-carboxamide;

5-[2-methyl-5-(trimethylsilyl)phenoxy]-*N*-{2-[3-(*N,N*-dimethylamino)propylamino]-4,6-dimethoxy-1,3-pyrimidin-5-yl}furan-2-carboxamide;

5-[2-methyl-5-(trimethylsilyl)phenoxy]-*N*-{2-[3-(morpholin-4-yl)propylamino]-4,6-dimethoxy-1,3-pyrimidin-5-yl}furan-2-carboxamide;

5-[2-methyl-5-(trimethylsilyl)phenoxy]-*N*-{2-[2-(pyrrolidin-1-yl)ethylamino]-4,6-dimethoxy-1,3-pyrimidin-5-yl}furan-2-carboxamide;

5-[2-methyl-5-(trimethylsilyl)phenoxy]-*N*-{2-[3-(1,3-imidaz-1-yl)propylamino]-4,6-dimethoxy-1,3-pyrimidin-5-yl}furan-2-carboxamide;

5-[2-bromo-5-(trimethylsilyl)phenoxy]-*N*-(2,6-dimethoxyphenyl)furan-2-carboxamide;

5-[2-bromo-5-(trimethylsilyl)phenoxy]-*N*-(2,4,6-trimethoxyphenyl)furan-2-carboxamide;

5-[2-bromo-5-(trimethylsilyl)phenoxy]-*N*-(2,4,6-trimethoxy-1,3-pyrimidin-5-yl)furan-2-carboxamide;

5-[2-bromo-5-(trimethylsilyl)phenoxy]-*N*-(2-methylamino-4,6-dimethoxy-1,3-pyrimidin-5-yl)furan-2-carboxamide;

5-[2-bromo-5-(trimethylsilyl)phenoxy]-*N*-{2-[3-(4-methylpiperazinyl)propylamino]-4,6-dimethoxy-1,3-pyrimidin-5-yl}furan-2-carboxamide;

5-[2-bromo-5-(trimethylsilyl)phenoxy]-*N*-{2-[3-(*N,N*-dimethylamino)propylamino]-4,6-dimethoxy-1,3-pyrimidin-5-yl}furan-2-carboxamide;

5-[2-bromo-5-(trimethylsilyl)phenoxy]-*N*-{2-[3-(morpholin-4-yl)propylamino]-4,6-dimethoxy-1,3-pyrimidin-5-yl}furan-2-carboxamide;

5-[2-bromo-5-(trimethylsilyl)phenoxy]-*N*-{2-[2-(pyrrolidin-1-yl)ethylamino]-4,6-dimethoxy-1,3-pyrimidin-5-yl}furan-2-carboxamide;

5-[2-bromo-5-(trimethylsilyl)phenoxy]-*N*-{2-[3-(1,3-imidaz-1-yl)propylamino]-4,6-dimethoxy-1,3-pyrimidin-5-yl}furan-2-carboxamide;

5-[2-methoxy-5-(trimethylsilyl)phenoxy]-*N*-(2,6-dimethoxyphenyl)furan-2-carboxamide;

5-[2-methoxy-5-(trimethylsilyl)phenoxy]-*N*-(2,4,6-trimethoxyphenyl)furan-2-carboxamide;

5-[2-methoxy-5-(trimethylsilyl)phenoxy]-*N*-(2,4,6-trimethoxy-1,3-pyrimidin-5-yl)furan-2-carboxamide;

5-[2-methoxy-5-(trimethylsilyl)phenoxy]-*N*-(2-methylamino-4,6-dimethoxy-1,3-pyrimidin-5-yl)furan-2-carboxamide;

5-[2-methoxy-5-(trimethylsilyl)phenoxy]-*N*-{2-[3-(4-methylpiperazin-1-yl)propylamino]-4,6-dimethoxy-1,3-pyrimidin-5-yl}furan-2-carboxamide;

5-[2-methoxy-5-(trimethylsilyl)phenoxy]-*N*-{2-[3-(*N,N*-dimethylamino)propylamino]-4,6-dimethoxy-1,3-pyrimidin-5-yl}furan-2-carboxamide;

5-[2-methoxy-5-(trimethylsilyl)phenoxy]-*N*-{2-[3-(morpholin-4-yl)propylamino]-4,6-dimethoxy-1,3-pyrimidin-5-yl}furan-2-carboxamide;

5-[5-(ethyldimethylsilyl)-2-methylphenoxy]-*N*-(2,6-dimethoxyphenyl)furan-2-carboxamide;

5-[5-(ethyldimethylsilyl)-2-methylphenoxy]-*N*-(2,4,6-trimethoxyphenyl)furan-2-carboxamide;

5-[5-(ethyldimethylsilyl)-2-methylphenoxy]-*N*-(2,4,6-trimethoxy-1,3-pyrimidin-5-yl)furan-2-carboxamide;

5-[5-(ethyldimethylsilyl)-2-methylphenoxy]-*N*-(2-methylamino-4,6-dimethoxy-1,3-pyrimidin-5-yl)furan-2-carboxamide;

5-[5-(ethyldimethylsilyl)-2-methylphenoxy]-*N*-{2-[3-(4-methylpiperazin-1-yl)propylamino]-4,6-dimethoxy-1,3-pyrimidin-5-yl}furan-2-carboxamide;

5-[5-(ethyldimethylsilyl)-2-methylphenoxy]-*N*-{2-[3-(*N,N*-dimethylamino)propylamino]-4,6-dimethoxy-1,3-pyrimidin-5-yl}furan-2-carboxamide;

5-[5-(ethyldimethylsilyl)-2-methylphenoxy]-*N*-{2-[3-(morpholin-4-yl)propylamino]-4,6-dimethoxy-1,3-pyrimidin-5-yl}furan-2-carboxamide;

5-{5-[(2,2-dimethylpropyl)dimethylsilyl]-2-methylphenoxy}-*N*-(2,6-dimethoxyphenyl)furan-2-carboxamide;

5-{5-[(2,2-dimethylpropyl)dimethylsilyl]-2-methylphenoxy}-*N*-(2,4,6-trimethoxyphenyl)furan-2-carboxamide;

5-{5-[(2,2-dimethylpropyl)dimethylsilyl]-2-methylphenoxy}-*N*-(2,4,6-trimethoxy-1,3-pyrimidin-5-yl)furan-2-carboxamide;

5-{5-[(2,2-dimethylpropyl)dimethylsilyl]-2-methylphenoxy}-*N*-(2-methylamino-4,6-dimethoxy-1,3-pyrimidin-5-yl)furan-2-carboxamide;

5-{5-[(2,2-dimethylpropyl)dimethylsilyl]-2-methylphenoxy}-*N*-{2-[3-(4-methylpiperazin-1-yl)propylamino]-4,6-dimethoxy-1,3-pyrimidin-5-yl}furan-2-carboxamide;

5-{5-[(2,2-dimethylpropyl)dimethylsilyl]-2-methylphenoxy}-*N*-{2-[3-(*N,N*-dimethylamino)propylamino]-4,6-dimethoxy-1,3-pyrimidin-5-yl}furan-2-carboxamide;

5-{5-[(2,2-dimethylpropyl)dimethylsilyl]-2-methylphenoxy}-*N*-{2-[3-(morpholin-4-yl)propylamino]-4,6-dimethoxy-1,3-pyrimidin-5-yl}furan-2-carboxamide;

5-{5-[1,1-dimethyl-2-(trimethylsilyl)ethyl]-2-methylphenoxy}-*N*-(2,6-dimethoxyphenyl)furan-2-carboxamide;

5-{5-[1,1-dimethyl-2-(trimethylsilyl)ethyl]-2-methylphenoxy}-*N*-(2,4,6-trimethoxyphenyl)furan-2-carboxamide;

5-{5-[1,1-dimethyl-2-(trimethylsilyl)ethyl]-2-methylphenoxy}-*N*-(2,4,6-trimethoxy-1,3-pyrimidin-5-yl)furan-2-carboxamide;

5-{5-[1,1-dimethyl-2-(trimethylsilyl)ethyl]-2-methylphenoxy}-*N*-(2-methylamino-4,6-dimethoxy-1,3-pyrimidin-5-yl)furan-2-carboxamide;

5-{5-[1,1-dimethyl-2-(trimethylsilyl)ethyl]-2-methylphenoxy}-*N*-{2-[3-(4-methylpiperazin-1-yl)propylamino]-4,6-dimethoxy-1,3-pyrimidin-5-yl}furan-2-carboxamide;

5-{5-[1,1-dimethyl-2-(trimethylsilyl)ethyl]-2-methylphenoxy}-*N*-{2-[3-(*N,N*-dimethylamino)propylamino]-4,6-dimethoxy-1,3-pyrimidin-5-yl}furan-2-carboxamide;

5-{5-[1,1-dimethyl-2-(trimethylsilyl)ethyl]-2-methylphenoxy}-*N*-{2-[3-(morpholin-4-yl)propylamino]-4,6-dimethoxy-1,3-pyrimidin-5-yl}furan-2-carboxamide;

5-{[2-methyl-5-(trimethylsilyl)phenyl]methyl}-*N*-(2,6-dimethoxyphenyl)furan-2-carboxamide;

5-{[2-methyl-5-(trimethylsilyl)phenyl]methyl}-*N*-(2,4,6-trimethoxyphenyl)furan-2-carboxamide;

5-{[2-methyl-5-(trimethylsilyl)phenyl]methyl}-*N*-(2,4,6-trimethoxy-1,3-pyrimidin-5-yl)furan-2-carboxamide;

5-{[2-methyl-5-(trimethylsilyl)phenyl]methyl}-*N*-(2-methylamino-4,6-dimethoxy-1,3-pyrimidin-5-yl)furan-2-carboxamide;

5-{[2-methyl-5-(trimethylsilyl)phenyl]methyl}-*N*-{2-[3-(4-methylpiperazin-1-yl)propylamino]-4,6-dimethoxy-1,3-pyrimidin-5-yl}furan-2-carboxamide;

5-{[2-methyl-5-(trimethylsilyl)phenyl]methyl}-*N*-{2-[3-(*N,N*-dimethylamino)propylamino]-4,6-dimethoxy-1,3-pyrimidin-5-yl}furan-2-carboxamide;

5-{[2-methyl-5-(trimethylsilyl)phenyl]methyl}-*N*-{2-[3-(morpholin-4-yl)propylamino]-4,6-dimethoxy-1,3-pyrimidin-5-yl}furan-2-carboxamide;

5-[2-methoxy-4-phenoxy-5-(trimethylsilyl)phenylthio]-*N*-[4,6-dimethoxy-(2-phenylamino)-1,3-pyrimidin-5-yl]furan-2-carboxamide;

5-{2-methoxy-5-[(2,2-dimethylpropyl)dimethylsilyl]phenoxy}-*N*-[2-(*N-tert*-butyloxycarbonylpiperidinyl-4'-amino)-4,6-dimethoxy-1,3-pyrimidin-5-yl]furan-2-carboxamide;

5-{2-methoxy-5-[(2,2-dimethylpropyl)dimethylsilyl]phenoxy}-*N*-{2-[3-(1,3-imidazol-1-yl)propylamino]-4,6-dimethoxy-1,3-pyrimidin-5-yl}furan-2-carboxamide;

5-{[(1,1-dimethylethyl)dimethylsilyl]phenoxy}-*N*-(2,4,6-trimethoxyphenyl)benzene-3-carboxamide;

5-[2-methoxy-4-(dimethylphenylsilyl)phenoxy]-*N*-{2-[2-(ethylamino)ethylamino]-4,6-dimethoxy-1,3-pyrimidin-5-yl}furan-2-carboxamide;

5-[4-chloro-2-methyl-5-(trimethylsilyl)phenoxy]-*N*-(2,4,6-trimethoxy-1,3-pyrimidin-5-yl}furan-2-carboxamide;

5-[4-chloro-2-methoxy-6-methyl-3-(trimethylsilyl)phenoxy]-*N*-{2-[3-(4-methylpiperazin-1-yl)propylamino]-4,6-dimethoxy-1,3-pyrimidin-5-yl} furan-2-carboxamide;

5-[2-methyl-5-(propyldimethylsilyl)phenoxy]-*N*-(2,4,6-trimethoxyphenyl)furan-2-carboxamide;

5-[2-methyl-5-(trimethylsilyl)phenoxy]-*N*-[2-(*N*-*tert*-butyloxycarbonylpiperidinyl-4'-amino)-4,6-dimethoxy-1,3-pyrimidin-5-yl]furan-2-carboxamide;

5-[2-methoxy-5-(trimethylsilyl)phenoxy]-*N*-[2-(3-methoxycarbonylpropylamino)-4,6-dimethoxy-1,3-pyrimidin-5-yl]furan-2-carboxamide;

5-[2-bromo-5-(trimethylsilyl)phenoxy]-*N*-{2-(2-(propylamino)ethylamino)]-4,6-dimethoxy-1,3-pyrimidin-5-yl} furan-2-carboxamide;

5-[2-bromo-5-(trimethylsilyl)phenoxy]-*N*-{2-[(2-aminoethyl)propylamino)]-4,6-dimethoxy-1,3-pyrimidin-5-yl} furan-2-carboxamide;

5-[2-bromo-5-(trimethylsilyl)phenoxy]-*N*-(2-chloro-4,6-dimethoxy-1,3-pyrimidin-5-yl)furan-2-carboxamide;

5-{2-methyl-4-[(2,2-dimethylpropyl)dimethylsilyl]phenoxy}-*N*-(2,4,6-trimethoxyphenyl)furan-2-carboxamide;

5-{2-methyl-4-[1,1-dimethyl-2-(trimethylsilyl)ethyl]phenoxy}-*N*-(2,4,6-trimethoxyphenyl)furan-2-carboxamide;

5-[2-methyl-4,5-bis(trimethylsilyl)phenoxy]-*N*-(2,4,6-trimethoxyphenyl)furan-2-carboxamide;

5-[2-methyl-4-(trimethylsilyl)phenoxy]-*N*-(2,6-dimethoxyphenyl)furan-2-carboxamide;

5-[2-methyl-4-(trimethylsilyl)phenoxy]-*N*-(2,4,6-trimethoxyphenyl)furan-2-carboxamide;

5-[2-methyl-4-(trimethylsilyl)phenoxy]-*N*-(2,4,6-trimethoxy-1,3-pyrimidin-5-yl)furan-2-carboxamide;

5-[2-methyl-4-(trimethylsilyl)phenoxy]-*N*-(2-methylamino-4,6-dimethoxy-1,3-pyrimidin-5-yl)furan-2-carboxamide;

5-[2-methyl-4-(trimethylsilyl)phenoxy]-*N*-{2-[3-(4-methylpiperazin-1-yl)propylamino]-4,6-dimethoxy-1,3-pyrimidin-5-yl} furan-2-carboxamide;

5-[2-methyl-4-(trimethylsilyl)phenoxy]-*N*-{2-[3-(*N,N*-dimethylamino)propylamino]-4,6-dimethoxy-1,3-pyrimidin-5-yl} furan-2-carboxamide;

5-[2-methyl-4-(trimethylsilyl)phenoxy]-*N*-{2-[3-(morpholin-4-yl)propylamino]-4,6-dimethoxy-1,3-pyrimidin-5-yl} furan-2-carboxamide;

5-[2-methyl-4-(trimethylsilyl)phenoxy]-*N*-{2-[2-(pyrrolidin-1-yl)ethylamino]-4,6-dimethoxy-1,3-pyrimidin-5-yl} furan-2-carboxamide;

5-[2-methyl-4-(trimethylsilyl)phenoxy]-*N*-{2-[3-(1,3-imidaz-1-yl)propylamino]-4,6-dimethoxy-1,3-pyrimidin-5-yl} furan-2-carboxamide;

5-[2-chloro-5-(trimethylsilyl)phenoxy]-*N*-(2,6-dimethoxyphenyl)furan-2-carboxamide;

5-[2-chloro-5-(trimethylsilyl)phenoxy]-*N*-(2,4,6-trimethoxyphenyl)furan-2-carboxamide;

5-[2-chloro-5-(trimethylsilyl)phenoxy]-*N*-(2,4,6-trimethoxy-1,3-pyrimidin-5-yl)furan-2-carboxamide;

5-[2-chloro-5-(trimethylsilyl)phenoxy]-*N*-(2-methylamino-4,6-dimethoxy-1,3-pyrimidin-5-yl)furan-2-carboxamide;

5-[2-chloro-5-(trimethylsilyl)phenoxy]-*N*-{2-[3-(4-methylpiperazin-1-yl)propylamino]-4,6-dimethoxy-1,3-pyrimidin-5-yl} furan-2-carboxamide;

5-[2-chloro-5-(trimethylsilyl)phenoxy]-*N*-{2-[3-(*N,N*-dimethylamino)propylamino]-4,6-dimethoxy-1,3-pyrimidin-5-yl} furan-2-carboxamide;

5-[2-chloro-5-(trimethylsilyl)phenoxy]-*N*-{2-[3-(morpholin-4-yl)propylamino]-4,6-dimethoxy-1,3-pyrimidin-5-yl} furan-2-carboxamide;


5-[2-chloro-5-(trimethylsilyl)phenoxy]-*N*-{2-[2-(pyrrolidin-1-yl)ethylamino]-4,6-dimethoxy-1,3-pyrimidin-5-yl} furan-2-carboxamide; and

5-[2-chloro-5-(trimethylsilyl)phenoxy]-*N*-{2-[3-(1,3-imidaz-1-yl)propylamino]-4,6-dimethoxy-1,3-pyrimidin-5-yl} furan-2-carboxamide[[:]].


20 (Currently amended). [[A]] The compound according to ~~any preceding~~ claim 1, which is in the form of a single enantiomer or diastereomer or tautomer.

21 (Canceled).

22 (Currently amended). A pharmaceutical composition comprising a compound of formula (I) or formula (II)



(I)



(II)

wherein

D is $-(CH_2)_n-$, $-C(=X)-$, $-O-$, $-S(O)_m-$, $-C(=X)N(R^c)-$, $-C(R^b)_2-$, $-C(R^b)=C(R^b)-$, $-CH(R^b)CH(R^b)-$;

E is optionally present and is $-(CH_2)_n-$, $-N(R^d)-$, $-(CH_2)_nN(R^d)-$ or $-N(R^d)(CH_2)_n-$;

F is $-C(=X)-$ or $-N(R^d)-$;

G is $-(CH_2)_n-$, $-N(R^d)-$, $-(CH_2)_nN(R^d)-$ or $-N(R^d)(CH_2)_n-$;

J is optionally present and is $-O-$, $-N(R^c)C(=X)-$, $-C(=X)N(R^c)-$, $-S(O)_m-$, $-N(R^c)S(O)_m-$, $-S(O)_mN(R^c)-$ or $-N(R^c)-$;

K is optionally present and is alkylene optionally substituted with R^b; or K is cycloalkylene, cycloalkenylene, arylene, heterocycloalkylene, heterocycloalkylene or heteroarylene, any of which is optionally substituted with R^a;

L is hydrogen, halogen, $-N(R^f)_2$, cycloalkyl, cycloalkenyl, aryl, heterocycloalkyl, heterocycloalkenyl or heteroaryl, any of which is optionally substituted with R^a, $-C(=X)OR^d$, $-OH$, $-OR^c$, $-C(=X)N(R^b)(R^c)$, $-S(O)_mN(R^b)(R^c)$ or $-CN$;

each R^a is the same or different and is hydrogen, halogen, alkyl, aryl, hydroxy, alkoxy, $-alkoxy-(CH_2)_nC(O)_2R^b$, $-O-aryl$, $-C(=X)R^c$, $-NO_2$, $-CN$, $-N(R^c)C(=X)R^c$, $-C(=X)N(R^c)_2$, $-S(O)_2N(R^c)_2$ or $-N(R^c)_2$;


each R^b is the same or different and is hydrogen or alkyl;

each R^c is the same or different and is alkyl, cycloalkyl, $-alkyl-aryl$, $-alkyl-cycloalkyl$ or aryl optionally substituted with R^a;


each R^d is the same or different and is hydrogen, alkyl or aryl optionally with R^a;
each R^c is the same or different and is hydrogen, alkyl; or R^c is aryl or heteroaryl,
either of which is optionally substituted with R^a;
each R^f is the same or different and is hydrogen or alkyl; or R^f-N-R^f taken together
form heterocycloalkyl, heterocycloalkenyl or heteroaryl;
each X is the same or different and is oxygen or sulphur;
Y and Z are the same or different and are each hydrogen, halogen, alkyl, hydroxy,
alkoxy, -CN, -N(R^d)C(=X)R^c, -C(=X)N(R^c)(R^d), -S(O)_m-R^c, -N(R^c)(R^d)S(O)₂,
-S(O)₂N(R^c)(R^d), -N(R^c)₂, -Si(R^c)₃, -alkyl-Si(R^c)₃, aryl optionally substituted with R^a or -O-
aryl optionally substituted with R^a;
Rings 1 and 2 are the same or different and are each arylene or heteroarylene, either
of which is optionally substituted with R^a;
each m is the same or different and is 0, 1 or 2; and
each n is the same or different and is 0, 1, 2, or 3;
with the provisos that at least one of Y and Z comprises a silicon atom and that the
compound does not comprise a N-N single bond;
or a pharmaceutically acceptable salt thereof;
~~a compound of any of claims 1 to 20~~ and a pharmaceutically acceptable diluent or carrier.

23 (Currently amended). The method, according to claim 30, Use of a compound of
~~any of claims 1 to 20, for the manufacture of a medicament~~ for cancer therapy.

24 (Currently amended). A method Use of a compound of any of claims 1 to 20,
~~for the manufacture of a medicament~~ for the treatment or prevention of endometriosis, uterine
 myoma, an ovarian disease, a mammary cystic disease, prostatic hypertrophy, amenorrhea,
 precocious puberty, premenstrual syndrome, a sex-steroid-dependent pathophysiology or
 benign prostatic hyperplasia, or to arrest spermatogenesis, wherein said method comprises
administering, to a patient in need of such treatment, a compound of formula (I) or formula
(II)



(I)



(II)

wherein

D is $-(CH_2)_n-$, $-C(=X)-$, $-O-$, $-S(O)_m-$, $-C(=X)N(R^c)-$, $-C(R^b)_2-$, $-C(R^b)=C(R^b)-$, $-CH(R^b)CH(R^b)-$;

E is optionally present and is $-(CH_2)_n-$, $-N(R^d)-$, $-(CH_2)_nN(R^d)-$ or $-N(R^d)(CH_2)_n-$;

F is $-C(=X)-$ or $-N(R^d)-$;

G is $-(CH_2)_n-$, $-N(R^d)-$, $-(CH_2)_nN(R^d)-$ or $-N(R^d)(CH_2)_n-$;

J is optionally present and is $-O-$, $-N(R^c)C(=X)-$, $-C(=X)N(R^c)-$, $-S(O)_m-$, $-N(R^c)S(O)_m-$, $-S(O)_mN(R^c)-$ or $-N(R^c)-$;

K is optionally present and is alkylene optionally substituted with R^b ; or K is cycloalkylene, cycloalkenylene, arylene, heterocycloalkylene, heterocycloalkylene or heteroarylene, any of which is optionally substituted with R^a ;

L is hydrogen, halogen, $-N(R^f)_2$, cycloalkyl, cycloalkenyl, aryl, heterocycloalkyl, heterocycloalkenyl or heteroaryl, any of which is optionally substituted with R^a , $-C(=X)OR^d$, $-OH$, $-OR^c$, $-C(=X)N(R^b)(R^c)$, $-S(O)_mN(R^b)(R^c)$ or $-CN$;

each R^a is the same or different and is hydrogen, halogen, alkyl, aryl, hydroxy, alkoxy, $-alkoxy-(CH_2)_nC(O)_2R^b$, $-O-aryl$, $-C(=X)R^c$, $-NO_2$, $-CN$, $-N(R^c)C(=X)R^c$, $-C(=X)N(R^c)_2$, $-S(O)_2N(R^c)_2$ or $-N(R^c)_2$;

each R^b is the same or different and is hydrogen or alkyl;

each R^c is the same or different and is alkyl, cycloalkyl, $-alkyl-aryl$, $-alkyl-cycloalkyl$ or aryl optionally substituted with R^a ;

each R^d is the same or different and is hydrogen, alkyl or aryl optionally with R^a ;

each R^c is the same or different and is hydrogen, alkyl; or R^e is aryl or heteroaryl, either of which is optionally substituted with R^a;

each R^f is the same or different and is hydrogen or alkyl; or R^f-N-R^f taken together form heterocycloalkyl, heterocycloalkenyl or heteroaryl;

each X is the same or different and is oxygen or sulphur;

Y and Z are the same or different and are each hydrogen, halogen, alkyl, hydroxy, alkoxy, -CN, -N(R^d)C(=X)R^c, -C(=X)N(R^c)(R^d), -S(O)_m-R^c, -N(R^c)(R^d)S(O)₂, -S(O)₂N(R^c)(R^d), -N(R^c)₂, -Si(R^c)₃, -alkyl-Si(R^c)₃, aryl optionally substituted with R^a or -O-aryl optionally substituted with R^a;

Rings 1 and 2 are the same or different and are each arylene or heteroarylene, either of which is optionally substituted with R^a;

each m is the same or different and is 0, 1 or 2; and

each n is the same or different and is 0, 1, 2, or 3;

with the provisos that at least one of Y and Z comprises a silicon atom and that the compound does not comprise a N-N single bond;

or a pharmaceutically acceptable salt thereof.

25 (Currently amended). The [[Use]] method, according to claim 24, for the treatment or prevention of endometriosis with pain, polycystic ovarian disease or secondary amenorrhea.

[[25]]26 (Currently amended). The method, according to claim 30, Use of a compound of any of claims 1 to 20, for the manufacture of a medicament for the treatment or prevention of Alzheimer's disease.

[[26]]27 (Currently amended). The method, accordint to claim 30, Use of a compound of any of claims 1 to 20, for the manufacture of a medicament for the treatment or prevention of HIV infection or AIDS.



[[27]]28 (Currently amended). The method, according to claim 30, Use of a compound of any of claims 1 to 20, for the manufacture of a medicament for the treatment or prevention of a disease caused by thymic malfunction.

[[28]]29 (Currently amended). The method, according to claim 30, Use according to claim 27, for the treatment or prevention of multiple sclerosis, rheumatoid arthritis or type 1 diabetes.

30 (New). A method for the treatment or prevention of one or more of the following conditions:

- a. cancer,
- b. Alzheimer's disease,
- c. HIV infection or AIDS,
- d. a disease caused by thymic malfunction, and
- e. multiple sclerosis, rheumatoid arthritis or type 1 diabetes,

wherein said method comprises administering, to a patient in need of such treatment, a compound of formula (I) or formula (II)



wherein

D is $-(CH_2)_n-$, $-C(=X)-$, $-O-$, $-S(O)_m-$, $-C(=X)N(R^c)-$, $-C(R^b)_2-$, $-C(R^b)=C(R^b)-$, $-CH(R^b)CH(R^b)-$;

E is optionally present and is $-(CH_2)_n-$, $-N(R^d)-$, $-(CH_2)_nN(R^d)-$ or $-N(R^d)(CH_2)_n-$;

F is $-C(=X)-$ or $-N(R^d)-$;

G is $-(CH_2)_n-$, $-N(R^d)-$, $-(CH_2)_nN(R^d)-$ or $-N(R^d)(CH_2)_n-$;

J is optionally present and is $-O-$, $-N(R^c)C(=X)-$, $-C(=X)N(R^c)-$, $-S(O)_m-$, $-N(R^c)S(O)_m-$, $-S(O)_mN(R^c)-$ or $-N(R^c)-$;

K is optionally present and is alkylene optionally substituted with R^b ; or K is cycloalkylene, cycloalkenylene, arylene, heterocycloalkylene, heterocycloalkylene or heteroarylene, any of which is optionally substituted with R^a ;

L is hydrogen, halogen, $-N(R^f)_2$, cycloalkyl, cycloalkenyl, aryl, heterocycloalkyl, heterocycloalkenyl or heteroaryl, any of which is optionally substituted with R^a , $-C(=X)OR^d$, $-OH$, $-OR^c$, $-C(=X)N(R^b)(R^c)$, $-S(O)_mN(R^b)(R^c)$ or $-CN$;

each R^a is the same or different and is hydrogen, halogen, alkyl, aryl, hydroxy, alkoxy, $-alkoxy-(CH_2)_nC(O)_2R^b$, $-O-aryl$, $-C(=X)R^c$, $-NO_2$, $-CN$, $-N(R^c)C(=X)R^c$, $-C(=X)N(R^c)_2$, $-S(O)_2N(R^c)_2$ or $-N(R^c)_2$;

each R^b is the same or different and is hydrogen or alkyl;

each R^c is the same or different and is alkyl, cycloalkyl, $-alkyl-aryl$, $-alkyl-cycloalkyl$ or aryl optionally substituted with R^a ;

each R^d is the same or different and is hydrogen, alkyl or aryl optionally with R^a ;

each R^e is the same or different and is hydrogen, alkyl; or R^e is aryl or heteroaryl, either of which is optionally substituted with R^a ;

each R^f is the same or different and is hydrogen or alkyl; or R^f-N-R^f taken together form heterocycloalkyl, heterocycloalkenyl or heteroaryl;

each X is the same or different and is oxygen or sulphur;

Y and Z are the same or different and are each hydrogen, halogen, alkyl, hydroxy, alkoxy, $-CN$, $-N(R^d)C(=X)R^c$, $-C(=X)N(R^c)(R^d)$, $-S(O)_m-R^c$, $-N(R^c)(R^d)S(O)_2$, $-S(O)_2N(R^c)(R^d)$, $-N(R^c)_2$, $-Si(R^c)_3$, $-alkyl-Si(R^c)_3$, aryl optionally substituted with R^a or $-O-aryl$ optionally substituted with R^a ;

Rings 1 and 2 are the same or different and are each arylene or heteroarylene, either of which is optionally substituted with R^a ;

each m is the same or different and is 0, 1 or 2; and

each n is the same or different and is 0, 1, 2, or 3;

with the provisos that at least one of Y and Z comprises a silicon atom and that the compound does not comprise a N-N single bond;

or a pharmaceutically acceptable salt thereof.